Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a con...
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10...
2024-04-05 15:00:02 ET Salim Syed from Mizuho Securities issued a price target of $99.00 for CYTK on 2024-04-05 12:19:00. The adjusted price target was set to $99.00. At the time of the announcement, CYTK was trading at $72.74. The overall price target consensus is at $6...
2024-04-05 08:19:03 ET More on Cytokinetics Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics gains amid renewed takeover specu...
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM ( F ollow-up, O pen-Label, R esearch E valuation of S ustained T reatment with Aficamten in HCM ), the ...
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Mon...
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
2024-03-26 14:01:03 ET More on Cytokinetics Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics drif...
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73 rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024. ...
2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) announced that the Company will host the ...
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17 th , 2024 at the Mission Bay Conference Ce...
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five presentations relat...